These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 25614665)

  • 1. Deciphering metabolic messages from the gut drives therapeutic innovation: the 2014 Banting Lecture.
    Drucker DJ
    Diabetes; 2015 Feb; 64(2):317-26. PubMed ID: 25614665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Multifaceted Roles of Adipose Tissue-Therapeutic Targets for Diabetes and Beyond: The 2015 Banting Lecture.
    Scherer PE
    Diabetes; 2016 Jun; 65(6):1452-61. PubMed ID: 27222389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture.
    Holst JJ
    Diabetes; 2021 Nov; 70(11):2468-2475. PubMed ID: 34711671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Banting lecture 2011: hyperinsulinemia: cause or consequence?
    Corkey BE
    Diabetes; 2012 Jan; 61(1):4-13. PubMed ID: 22187369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glucagon-like peptides--synthesis, biological actions and some clinical implications].
    Otto Buczkowska E; Dworzecki T
    Przegl Lek; 2004; 61(9):947-50. PubMed ID: 15803906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological actions and therapeutic potential of the glucagon-like peptides.
    Drucker DJ
    Gastroenterology; 2002 Feb; 122(2):531-44. PubMed ID: 11832466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathway.
    Yusta B; Matthews D; Flock GB; Ussher JR; Lavoie B; Mawe GM; Drucker DJ
    Mol Metab; 2017 Jun; 6(6):503-511. PubMed ID: 28580281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
    Drucker DJ
    Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COMPARATIVE GUT PHYSIOLOGY SYMPOSIUM: Comparative physiology of glucagon-like peptide-2: Implications and applications for production and health of ruminants.
    Connor EE; Evock-Clover CM; Walker MP; Elsasser TH; Kahl S
    J Anim Sci; 2015 Feb; 93(2):492-501. PubMed ID: 26020740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minireview: the glucagon-like peptides.
    Drucker DJ
    Endocrinology; 2001 Feb; 142(2):521-7. PubMed ID: 11159819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
    Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
    Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2.
    Drucker DJ; Yusta B
    Annu Rev Physiol; 2014; 76():561-83. PubMed ID: 24161075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.